In a welcome move, Ingevity saw its Relative Strength Rating improve from 63 to 74 on Wednesday.
When To Sell Stocks To Lock In Profits And Minimize Losses
This proprietary rating measures market leadership by showing how a stock's price action over the last 52 weeks compares to that of the other stocks in our database.
History reveals that the stocks that go on to make the biggest gains often have an 80 or better RS Rating as they begin their largest price moves. See if Ingevity can continue to rebound and hit that benchmark.
Ingevity is trying to complete a double bottom with a 50.09 entry. See if the stock can break out in volume at least 40% above average.
Ingevity saw both earnings and sales growth rise last quarter. Earnings-per-share increased from 0% to 111%. Revenue rose from -20% to -16%. The company is expected to report its latest performance numbers on or around Jul. 30.
The company earns the No. 6 rank among its peers in the Chemicals-Specialty industry group. Niagen Bioscience, Solaris Energy Infr and NewMarket are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
